Impact of Biosimilars on Oncology

FDA grants 2 breakthrough therapy designations to Temab-A, speeding development for hard-to-treat colorectal cancer and c-Met–expressing lung cancer.

Daniel Heng, MD, discusses how belzutifan plus lenvatinib fills an unmet need after immunotherapy in RCC, with insights on managing hypoxia and anemia and on sequencing.

Lyudmila Bazhenova, MD, explains why the updated taletrectinib label does not change her practice and reviews new WCLC subgroup data in ROS1+ NSCLC.

The approval of the adjuvant atezolizumab combination in dMMR colon cancer is supported by the phase 3 ATOMIC trial.

The SURVIVE trial of the targeted vaccine SurVaxM did not meet its primary OS end point due to longer-than-expected survival with standard of care in glioblastoma but showed benefit in patients aged 65 and below.

Interim phase 2 results show carotuximab plus apalutamide sharply extends progression-free survival in metastatic castration-resistant prostate cancer, prompting earlier-use trial changes.

Firmonertinib did not improve PFS in the phase 3 FURVENT trial in patients with EGFR exon 20 insertion–mutant NSCLC.

Sarah Premji, MD, of Sarah Cannon Research Institute, discusses community trial access, biomarker-driven drug development, and key breast cancer studies to watch.